River Blindness or onchocerciasis is caused by the prelarval (microfilaria) and adult stages of the filarial nematode Onchocerca volvulus. The disease is transmitted by the bite of certain species of female Simulium flies (black flies) that bite by day and are found near rapidly flowing rivers and streams. Onchocerciasis is endemic in more than 25 nations located in a broad band across the central part of Africa. Small endemic foci are also present in the Arabian Peninsula (Yemen) and in the Americas (Brazil, Colombia, Ecuador, Guatemala, southern Mexico, and Venezuela)
Researchers at Washington University School of Medicine in St. Louis have received a $7 million grant from the Bill & Melinda Gates Foundation aimed at eliminating river blindness and elephantiasis, two neglected tropical diseases that annually sicken millions.
New Smartphone technology has been developed that can detect and count wriggling parasitic worms in a drop of blood...
Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina.
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
The Drugs for Neglected Diseases initiative has been awarded US$ 10 million by the United States Agency for International Development to develop new treatments for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) - the first-ever USAID grant for neglected tropical disease research and development (R&D).
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.
Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie.
Almost $2 million is being invested by the Bill & Melinda Gates Foundation to help fight major parasitic diseases of the developing world.
A new test will accelerate global progress toward eliminating onchocerciasis, a leading cause of preventable blindness in Africa. PATH, an international nonprofit health organization, today announced the availability of the SD BIOLINE Onchocerciasis IgG4 rapid test, manufactured and distributed by Standard Diagnostics, Inc.
Despite decades of research, scientists have yet to pinpoint the exact cause of nodding syndrome (NS), a disabling disease affecting African children. A new report suggests that blackflies infected with the parasite Onchocerca volvulus may be capable of passing on a secondary pathogen that is to blame for the spread of the disease. New research is presented in the International Journal of Infectious Diseases.
Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).
Equatorial Guinea's infant mortality rate has decreased from 111 in 1994 to 65 per one thousand in 2011, said the country's Health Secretary of State, Maria del Carmen Andeme Ela. She also reported that the percentage of pregnant women receiving prenatal care from skilled health personnel has increase from 61% in 2000 to 91.3% this year.
Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.
Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.
The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.
The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.
Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.
The Liverpool School of Tropical Medicine (LSTM) is delighted that Emeritus Professor and Senior Professional Fellow, David Molyneux, has been awarded The Manson Medal, the Royal Society of Tropical Medicine and Hygiene's highest mark of distinction.
Filariasis refers to a group of diseases caused by parasitic worms, which are transmitted by blood feeding insects. Two species infect the lymphatic and blood systems causing lymphatic filariasis, which in some people can lead to gross swelling of the limbs and 'elephantiasis'.
Liverpool School of Tropical Medicine (LSTM) has received US$ 10 million from the Bill & Melinda Gates Foundation to continue their breakthrough drug discovery and development research against human filariasis - parasitic worm infections which cause river blindness and elephantiasis, some of the world’s most debilitating diseases affecting up to 150 million people in 83 countries throughout the tropics.